Previous Article | Next Article ![]()
Journal of Clinical Microbiology, March 2007, p. 1032-1034, Vol. 45, No. 3
0095-1137/07/$08.00+0 doi:10.1128/JCM.01884-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Division of Virology, Department of Medical Microbiology, University Hospital Aachen, RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany,1 Department of Pediatrics, University Hospital Aachen, RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany,2 Department of Pediatric Cardiology, University Hospital Aachen, RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany3
Received 10 September 2006/ Returned for modification 14 November 2006/ Accepted 24 December 2006
|
|
|---|
|
|
|---|
Our study included 94 hospitalized patients of <36 months of age (mean, 6 months) with assumed severe lower respiratory tract disease as defined by a high rate of oxygen therapy (68%). An underlying cardiac and/or pulmonary disease was present in 18%. In most cases RSV infection was the most important differential diagnosis (53.2%) because of the seasonal epidemiology and the clinical symptomatology including marked airway obstruction in 62%. We chose this patient collective as young children represent reportedly the age group of HBoV genome-positive patients exhibiting the severest symptoms. Among 75 patients investigated by chest X-ray studies, 72% had peribronchial and 23% had pneumonic infiltrates. Respiratory tract specimens collected from these children between November 2005 and April 2006 (76% nasopharyngeal washes, 21% tracheal secretions, 3% bronchoalveolar lavage [BAL] samples) were studied for adenoviruses, influenza A virus, influenza B virus, parainfluenzaviruses types 1 to 3, and RSV using antigen-specific immunofluorescence assays (IMAGEN respiratory screen; DAKO); for the hMPV using a PCR assay (2); and for HBoV using the PCR protocol described by Allender et al. (1). Specimens known to be positive for parvovirus B19 genotype 1 (n = 5), herpes simplex virus, human cytomegalovirus, Epstein-Barr virus, JC virus, adenovirus, papillomavirus, RSV, parainfluenza virus, influenza A virus, or influenza B virus (n = 3 for each virus) were analyzed as specificity controls.
Nucleic acid was extracted from 220 µl of each specimen by using a QIAamp virus Biorobot 9604 kit (QIAGEN, Hilden, Germany) and eluted with 60 µl of PCR-grade water. An aliquot of 5 µl was added to 15 µl of reaction mixture containing 3 mM MgCl2, a 0.5 µM concentration of each primer (1888 F, 542 R, and HBoV NP1 gene) (1), 0.15 µM fluorescein hybridization probe (GGAAGAGACACTGGCAGACAAC-fluorescein; TIB Molbiol, Berlin, Germany), 0.15 µM LC-Red 640 probe (LC-Red 640-CATCACAGGAGCAGGAGCCG), and 2 µl of enzyme mix (LightCycler FastStart DNA Master Hybridization Probes; Roche Applied Science, Mannheim, Germany). The experimental PCR protocol was as follows: an initial 10 min at 95°C for FastStart Taq polymerase activation, followed by 45 cycles of 2 s of denaturation at 95°C, 10 s of annealing at 54°C, and 15 s of extension at 72°C. Quantification of HBoV DNA was performed with a serial dilution of a plasmid standard containing the primer-spanning region of the NP1 gene. The amplicon of 354 bp was generated by PCR using DNA from an HBoV-positive specimen as a template and subsequently cloned into the vector pcDNA3.1/V5-His-TOPO (Invitrogen, Carlsbad, CA), resulting in the plasmid pcDNA-HBoV.
Of the 94 specimens included in this study, 26 (27.6%) were negative in all assays (Table 1); 50 (53.2%) were positive for RSV; 7 (7.4%) were positive for adenoviruses, influenzaviruses, or parainfluenzaviruses; and 5 (5.3%) were positive for the human metapneumovirus. HBoV could be detected in 12 (12.8%) specimens (83.3% were nasopharyngeal washes, 8.3% tracheal secretions, 8.3% BAL samples) of patients aged 1 to 30 months (mean, 7.8 months), five of whom were simultaneously infected with RSV (41.7%). In 3 of the 12 HBoV-positive patients, hospital-acquired infection was assumed as they developed respiratory symptoms after hospital treatment for other diseases for at least 4 weeks.
|
View this table: [in a new window] |
TABLE 1. Clinical and virological findings 94 young children with assumed viral lung infections
|
Cycle conditions for an HBoV-specific real-time PCR on the LightCycler instrument were established using primers and fluorophore probes as described above. The correlation between the crossing point and the log template concentration was determined with a dilution series of the standard quantification plasmid, pcDNA-HBoV. The analysis revealed a linear correlation (r = 1) between both parameters in a range between 103 and 1012 plasmid copies per ml of standard (Fig. 1A). To address the specificity of the assay, a panel of 35 samples positive for DNA viruses and respiratory viruses as described above was tested concomitantly. All samples were nonreactive by the HBoV-specific real-time PCR.
![]() View larger version (14K): [in a new window] |
FIG. 1. (A) Correlation between the crossing point and the log template concentration of an HBoV-specific real-time PCR using pcDNA-HBoV as a template. (B) HBoV viral load in respiratory specimens from 12 children with respiratory disease.
|
The data available so far indicate that HBoV may be responsible for a substantial share of respiratory tract infections in young children, particularly in those with underlying cardiopulmonary disease, narrowing the gap of infections with unknown etiology. Lu et al. (3) described an HBoV-specific real-time protocol using the exonuclease probe format. No absolute quantification of viral loads was given. The LightCycler PCR assay developed by us using the hybridization probe format allows the accurate detection and quantitative assessment of HBoV DNA in human specimens. Sensitivity and specificity of the assay are high. The specimens studied are dominated by low viral loads; only 25% of specimens had loads exceeding 104 genome equivalents/ml. Two hypotheses may explain the lack of correlation between the viral load and the clinical data. First, the nasopharyngeal washes, tracheal aspirates, and BAL samples were not collected by means of a standardized protocol for virus quantification but during routine procedures aiming at qualitative detection of viral particles, which may result in variable viral loads. Second, viral loads may change rapidly in the course of a disease, resulting in variable quantification results. The samples, however, had not been taken at predefined time points. Prospective studies based on quantitative HBoV detection are needed to specify the clinical impact of HBoV and to define the kinetics of the HBoV viral load.
Published ahead of print on 10 January 2007. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»